Sector ratings Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 21:00:00 02/07/2026 BST			5-day change	1st Jan Change
3.630 ^USD	+4.91%		+19.41%	+32.00%

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	414M	-	BBB	-	-
LONZA GROUP AG	49.92B		AAA
REVOLUTION MEDICINES, INC.	40.23B	-	B	-	-
IQVIA HOLDINGS INC.	34.55B		AAA
BEONE MEDICINES AG	33.09B		-
CELLTRION, INC.	27.51B		A
ASCENDIS PHARMA A/S	17.05B	-	-	-	-
MEDPACE HOLDINGS, INC.	15.92B		BBB
EUROFINS SCIENTIFIC SE	13.86B		AA
IONIS PHARMACEUTICALS, INC.	13.52B	-	A	-	-
ICON PUBLIC LIMITED COMPANY	13.26B		AAA
ABIVAX	13.31B	-	BBB	-	-
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	11.11B		AA
BIO-TECHNE CORPORATION	11.04B		AA
TEMPUS AI, INC.	10.82B		A		-
APOGEE THERAPEUTICS, INC.	9.96B	-	B	-	-
KYMERA THERAPEUTICS, INC.	9.34B	-	BBB	-	-
ALKERMES PLC	9.1B		A
PRAXIS PRECISION MEDICINES, INC.	8.88B	-	B	-	-
PROTAGONIST THERAPEUTICS, INC.	8.46B		BB		-
Average	17.57B		A
Weighted average by Cap.			A